Gastric cancer
Section snippets
Incidence and mortality
Stomach cancer is one of the most common cancers in Europe ranking fifth [1] after lung, prostate, colorectal and bladder cancers in men and breast, colorectal, lung and cancer of the corpus uteri in women. In Europe, each year there are some 192,000 new cases, representing about 23% of all malignant neoplasms [2]. The male-to-female ratio in incidence rates is about 1.6:1 [2].
The incidence of stomach cancer is higher in lower social classes, but has for many years been declining steadily by
Histogenesis
Gastric carcinomas do not arise de novo from normal epithelium, but occur through successive changes. These are well-characterized for the intestinal type of human gastric cancer, whereas, lesions predisposing to the development of the diffuse type of gastric cancer are not yet well understood. The development of the intestinal type gastric cancer includes the transformation of the normal mucosa into a mucosa that resembles intestinal epithelium (intestinal metaplasia). The presence of
Signs and symptoms
Unfortunately, most patients with gastric cancer at an early stage have mild or no symptoms. The main reason for late diagnosis is that patients typically present with vague and non-specific symptoms: mild upper gastrointestinal distress (heartburn), flatulence, abdominal fullness prematurely after meals, excessive belching, and at this point only rarely nausea/vomiting and pain occur. Approximately 30% of all patients with EGC have a long history of dyspepsia, which is indistinguishable from
Criteria for stage classification
Treatment decisions are usually made in reference to the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) [76], [77].
TNM Classification [77]
Primary tumour (T)TX: primary tumour cannot be assessed T0: no evidence of primary tumour Tis: carcinoma in situ: intraepithelial tumour without invasion of the lamina propria T1: tumour invades lamina propria or submucosa T2: tumour invades muscularis propria or subserosa T2a: tumour invades muscularis propria T2b: tumour invades subserosa T3:
Prognostic and risk factors
Although its incidence in developed countries has declined over the last three decades, gastric cancer remains the second most common cancer worldwide [100]. Prognosis continues to be poor, with 5-year survival rates of approximately 20% [101], [102], [103]. Recurrence following surgery is a major problem, and is often the ultimate cause of death. Tumour remaining in a patient after gastric resection with curative intent is categorized by a system known as R classification and indicates the
Overall treatment strategy
Surgical resection of the primary tumour and regional lymph nodes is the treatment of choice for gastric cancer. The extent of disease, the operative procedure, and patient selection are crucial in optimizing outcome. Adjuvant therapy (mainly, chemotherapy ± radiotherapy) still warrants further evaluation for high-risk (T3-4, N+) gastric cancer patients. Neoadjuvant therapy may reduce tumour mass enabling resection with potentially curative intent. When the disease is metastatic, treatment of
Late sequelae
Early recurrence of gastric cancer is difficult to identify and there are few opportunities to salvage patients with recurrent disease. It is unusual to see local-regional failure as the only component of relapse and in most cases relapse is associated with distant progression of disease and the disease is so not curable. Most of the local failures are distributed in the gastric bed (more than 75%), followed by the anastomosis or stump, and in the regional lymph nodes [223], [336]. Locally
General aims
In a general population of patients treated curatively for gastric cancer, approximately 40–60% of them will develop a recurrence. About 75–80% of these will occur within 2 years, and in nearly 98% of patients within 5 years from surgery [342], [343]. Local-regional disease as the only site of failure occurs in 23–56% of patients; by contrast, distant organ metastases as single site of relapse is quite rare (6%), and are generally found in the setting of advanced locoregional or peritoneal
References (350)
- et al.
Gastric cancer epidemiology and risk factors
J Clin Epidemiol
(2003) - et al.
EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary
Ann Oncol
(2003) - et al.
Comparison of stomach cancer incidence and survival in four continents
Eur J Cancer
(2003) - et al.
Cancer prevalence in European registry areas
Ann Oncol
(2002) - et al.
A model for gastric cancer epidemiology
Lancet
(1975) - et al.
Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading
Hum Pathol
(1997) - et al.
Endoscopic diagnosis of advanced gastric cancer. Factors influencing yield
Gastroenterology
(1975) - et al.
Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma
Gastroenterology
(1982) - et al.
The use of serologic tumor markers in gastrointestinal malignancies
Hematol Oncol Clin North Am
(1994) - et al.
Modern staging in gastric cancer
Surg Oncol
(2000)
Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms
Semin Nucl Med
Cancer incidence, mortality and prevalence in the European Union
Cancer survival trends in England and Wales 1971–1995: deprivation and NHS region
Upper gastrointestinal tract cancers: oesophagus, stomach, liver, gallbladder and biliary ducts, pancreas
Epidemiol Prev
Survival of cancer patients in Europe: the EUROCARE-3 study
Ann Oncol
Electronic availability of EUROCARE-3 data: a tool for further analysis
Ann Oncol
Survival of cancer patients in Finland 1955–1994
Acta Oncol
Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy
J Natl Cancer Inst
Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. The Helsinki Gastritis Study Group
Scand J Gastroenterol
Smoking and the risk of gastric cancer in the European prospective investigation into cancer and nutrition (EPIC)
Int J Cancer
An international association between Helicobacter pylori infection and gastric cancer
Lancet
Review article: long-term Helicobacter pylori infection-from gastritis to gastric cancer
Aliment Pharmacol Ther
Pernicious anemia and subsequent cancer. A population-based cohort study
Cancer
Cancer incidence in atomic bomb survivors. Part II. Solid tumors, 1958–1987
Radiat Res
Cancer following radiotherapy for peptic ulcer
J Natl Cancer Inst
Family history and risk of stomach cancer in Italy
Cancer Epidemiol Biomarkers Prev
Family history and the risk of stomach and colorectal cancer
Cancer
Family history and risk of stomach cancer in Warsaw, Poland
Eur J Cancer Prev
Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
N Engl J Med
Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer
Jpn J Cancer Res
Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening
J Med Screen
Intestinal metaplasia of the stomach. A status report
Cancer
Clinical implications of recent developments in gastric cancer pathology and epidemiology
Semin Oncol
Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention
Cancer Res
Gastric cancer: pathology
High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma
Gut
Geschwulste des Magens and Duodenums
Tumours of the stomach
The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification
Acta Pathol Microbiol Scand
News of TNM and its use for classification of gastric cancer
World J Surg
Gastric carcinoma. A pathobiological classification
Cancer
Pathology of early gastric cancer
Pathomorphological diagnosis. Definition and gross classification of early gastric cancer
Gann Monogr
Prospective study of “early” gastric cancer
Int J Cancer
Persistence of mucosal gastric carcinomas for 8 and 6 years in two patients
Arch Pathol Lab Med
Pathologic and phenotypic features of gastric cancer
Semin Oncol
Cited by (85)
The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model
2015, Toxicology in VitroCitation Excerpt :Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death in the world (Jemal et al., 2011). Two thirds of patients with gastric cancer have locally advanced or metastatic disease at diagnosis, generally owing to the absence of specific symptoms that renders early diagnosis of this disease difficulty (Catalano et al., 2005). Up to one half of patients have recurrent disease after curative surgery, and the outcomes for these patients are still very poor, with an estimated 5-year survival rate in only 20% of the patients (Hohenberger and Gretschel, 2003; Kamangar et al., 2006; Yoong et al., 2011).
Prognostic impact and immunotherapeutic implications of NETosis-related gene signature in gastric cancer patients
2024, Journal of Cellular and Molecular Medicine